BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 8980862)

  • 1. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolones and multidrug-resistant tuberculosis.
    Maranetra KN
    Chemotherapy; 1999; 45 Suppl 2():12-8. PubMed ID: 10449893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multidrug-resistant tuberculosis in Indonesia.
    Hadiarto M; Tjandra YA; Hudoyo A
    Chemotherapy; 1996; 42 Suppl 3():24-9. PubMed ID: 8980865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
    Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
    Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofloxacin in multidrug resistant tuberculosis.
    Walwaikar PP; Morye VK; Gawde AS
    J Indian Med Assoc; 2003 Mar; 101(3):210-2. PubMed ID: 14603981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multidrug-resistant tuberculosis in Taiwan.
    Suo J; Yu MC; Lee CN; Chiang CY; Lin TP
    Chemotherapy; 1996; 42 Suppl 3():20-3; discussion 30-3. PubMed ID: 8980864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug susceptibility patterns of Mycobacterium tuberculosis and clinical outcomes of drug-resistant tuberculosis at Srinagarind Hospital, a tertiary care center in northeastern Thailand.
    Reechaipichitkul W; Tubtim S; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2011 Sep; 42(5):1154-62. PubMed ID: 22299441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead.
    van Maaren PJ
    Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
    Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
    Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
    Pietersen E; Anderson K; Cox H; Dheda K; Bian A; Shepherd BE; Sterling TR; Warren RM; van der Heijden YF
    PLoS One; 2023; 18(2):e0281097. PubMed ID: 36780443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
    Kuo CY; Wang WH; Huang CH; Chen YH; Lu PL
    J Microbiol Immunol Infect; 2018 Feb; 51(1):88-93. PubMed ID: 28698044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
    Pracharktam R; Angkananukool K; Vibhagool A
    J Med Assoc Thai; 2001 Sep; 84(9):1241-5. PubMed ID: 11800295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.